Ventas price target lowered to $71 from $72 at Scotiabank
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTR:
Disclaimer & DisclosureReport an Issue
Ventas Inc: Strong Q1 2025 Performance in Senior Housing
Ventas Inc. Highlights Strong Q1 Performance and Growth
Ventas price target raised to $79 from $78 at Wedbush
Welltower price target raised to $169 from $167 at Wedbush
Strong Q1 2025 Performance and Strategic Acquisitions Justify Buy Rating for Ventas
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
14 hours ago
- CNBC
Ives: Musk suing Apple would be a massive headache and headwind
Dan Ives, Wedbush global head of tech research, tells Worldwide Exchange Musk's potential Apple lawsuit could escalate fast, as App Store placement is critical for Grok and X adoption.
Yahoo
2 days ago
- Yahoo
Wedbush Keeps Tesla (TSLA) Outperform, Expects a Huge Upside
Tesla, Inc. (NASDAQ:TSLA) is one of the best battery tech stocks to buy right now. Wedbush analyst Daniel Ives is very positive about Tesla, Inc. (NASDAQ:TSLA) and thinks the company has a strong future ahead. He gave Tesla stock an Outperform rating on August 4, and kept his price target at $500. With the stock trading at $322.50, this means there is a possible upside of around 55%. That shows Ives believes Tesla can grow a lot more. Copyright: wolandmaster / 123RF Stock Photo A big reason for this belief is the upcoming refresh of the Model Y. Many people are waiting for the new version, and it could help Tesla sell more cars. Also, Tesla is working hard on self-driving technology, and the planned robotaxi is expected to be a big step forward. If that project does well, it could open up a new area of business for Tesla. Wedbush also said that the current political climate under a Trump administration could make things easier for Tesla when it comes to rules and regulations. That might help the company move faster and focus more on its new products. Ives sees many reasons to stay confident in Tesla. Between the new cars, the robotaxi, and support from the government, the company could keep growing. With a stock price much lower than the $500 target, some investors may see this as a good opportunity. Tesla is a battery technology company because it designs and manufactures advanced lithium-ion battery cells, energy storage products like Powerwall and Megapack, and integrates these technologies into its electric vehicles and energy grid solutions, driving innovation in sustainable energy storage and usage. While we acknowledge the potential of TSLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
Key Points Merck is an industry giant that has proved time and again it can innovate for the future. Ventas has positioned itself to grow its business and its dividend. Omega Healthcare Investors has survived the storm, and now it is ready to ride the wave. 10 stocks we like better than Merck › If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge risks. Three solid options that you might want to buy hand over fist right now are Merck (NYSE: MRK), Ventas (NYSE: VTR), and Omega Healthcare Investors (NYSE: OHI). Here's a primer on each one. 1. Merck is a high-yield survivor Merck's dividend yield is a pleasing 4.1% or so, more than twice the healthcare sector's average. The company has increased its payout annually for 15 consecutive years. From this standpoint, it is an attractive dividend stock, but what about the business? Merck is one of the world's largest pharmaceutical companies. Discovering new drugs is hard work, and it usually doesn't happen in a linear fashion. Right now, investors appear concerned that Merck's current patents will expire before it finds a new blockbuster to replace its older drugs. That's not unreasonable, since it is highly reliant on the revenue of just one drug right now (oncology treatment Keytruda). But this isn't an unusual development; it is kind of normal for drug companies to go through periods like this. What's important to note is that Merck's strong research and development capabilities and its scale (it can fairly easily buy smaller companies to bolster its drug pipeline if it needs to) have allowed it to thrive over the long term. And that has allowed the dividend to trend reliably higher for decades, though it has not increased every single year. If you can handle buying while others are selling, Merck looks like an attractive choice right now. Its yield is near the highest levels since the Great Recession. 2. Ventas cut its dividend, but now it's set to grow Ventas is a real estate investment trust (REIT) specializing in senior housing, with a dividend yield of 2.8%. That's not bad, but it's not exactly an earth-shattering figure. And on top of that, the REIT cut its dividend during the pandemic. It was the right move, given that senior housing facilities were particularly hard hit during that time. And the dividend cut allowed Ventas to work with its tenants and shift its business approach in a more growth-focused direction. Specifically, Ventas increased its exposure to properties that it both owns and operates (technically, it hires a property manager). This allows the revenue and costs to flow directly onto the income statement. When times are tough, like during the pandemic, that's bad news. When times are flush, however, these assets can supercharge earnings. Senior housing has come back strongly from the pandemic hit. And the aging demographics of the country suggest there's more growth to come. The big story, however, is that dividend increases have resumed. And given the growth-focused nature of the business right now -- adjusted funds from operations rose a heady 9% year over year in the second quarter -- it is reasonable to expect dividend raises to be quite attractive in the years ahead. 3. Omega Healthcare Investors is still out of favor Omega Healthcare's dividend yield is a lofty 6.7%. The payout hasn't been increased in years, but it also hasn't been cut. Like Ventas, Omega is a REIT that owns senior housing properties, and they were hard hit during the pandemic. Omega chose to hold the line on its dividend as it worked with its tenants. The portfolio repositioning has been difficult, but now that the world has mostly moved past the pandemic, things are starting to improve. Adjusted FFO rose around 8% in the second quarter. That strong showing isn't quite as big an opportunity on the dividend front here, however, because its payout remained high throughout the pandemic period. But it is a sign that Omega's payout is likely sustainable as it gets back on the growth track, including buying new properties. Ventas' exposure to senior housing and the graying of the country are growth engines. Omega's exposure to this same thing is a recovery engine. If you need income today, buying into its turnaround story will probably be more attractive to you than buying Ventas. Three solid dividend choices in the healthcare sector Even when the average healthcare stock has a miserly 1.8% yield, you can still find very attractive income options. Merck is a tried-and-true dividend payer with a well-run business and attractive yield. Ventas, which also has an attractive yield, repositioned itself for growth during the pandemic, and that is now starting to shine through on the dividend side of things. And Omega muddled through the pandemic without a dividend cut, leaving it with a high yield today and a strengthening business. August could be a great time to buy one or more of these healthcare dividend stocks. Should you buy stock in Merck right now? Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Merck wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy. 3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August was originally published by The Motley Fool
